Research Article
New-Onset Diabetes and Glucose Regulation Are Significant Determinants of Left Ventricular Hypertrophy in Renal Transplant Recipients
Table 1
The clinical and biochemical parameters of patients according to NODAT groups.
| | | Patients with NODAT
(: 57) | Patients without NODAT
(: 102) | value |
| | Age (years) | 43.2 ± 10.7 | 37.0 ± 10.3 | 0.0001 | | Gender (M) | 35 (60.3%) | 83 (68.0%) | 0.198 | | Dialysis duration (months) | 56.5 ± 59.1 | 32.1 ± 39.0 | 0.010 | | Posttransplant duration (months) | 50.3 ± 59.9 | 57.4 ± 54.5 | 0.393 | | Pretx T. Chol (mg/dL) | 173.8 ± 45.9 | 171.3 ± 50.9 | 0.296 | | Pretx LDL Chol (mg/dL) | 92.6 ± 33.8 | 97.3 ± 34.3 | 0.506 | | Pretx HDL Chol (mg/dL) | 41.1 ± 14.5 | 42.7 ± 17.9 | 0.457 | | Pretx triglyceride (mg/dL) | 185.6 ± 125.14 | 158.4 ± 86.4 | 0.139 | | GFR (mL/min) | 68.68 ± 23.08 | 69.44 ± 24.9 | 0.841 | | Creatinine (mg/dL) | 1.2 ± 0.5 | 1.3 ± 0.5 | 0.472 | | Albumin (g/L) | 4.0 ± 0.4 | 4.1 ± 0.3 | 0.169 | | Hemoglobin (g/dL) | 13.2 ± 1.9 | 13.2 ± 1.9 | 0.832 | | T. Chol (mg/dL) | 215.9 ± 66.3 | 209.0 ± 46.4 | 0.483 | | LDL Chol (mg/dL) | 116.4 ± 40.7 | 119.7 ± 34.3 | 0.599 | | HDL Chol (mg/dL) | 47.7 ± 15.6 | 49.0 ± 13.4 | 0.605 | | Triglyceride (mg/dL) | 198.2 ± 93.1 | 164.3 ± 101.9 | 0.030 | | Calcium (mg/dL) | 9.4 ± 0.5 | 9.2 ± 0.6 | 0.475 | | Phosphorus (mg/dL) | 3.1 ± 0.7 | 3.2 ± 0.7 | 0.248 | | PTH (pcg/mL) | 193.4 ± 24.4 | 148.8 ± 96.9 | 0.092 | | Glucose (mg/dL) | 136.2 ± 52.2 | 87.3 ± 9.2 | 0.0001 | | Office SBP (mmHg) | 134.4 ± 24.5 | 122.0 ± 45.1 | 0.023 | | Office DBP (mmHg) | 83.3 ± 16.0 | 76.9 ± 28.5 | 0.065 | | HbA1c | 7.39 ± 1.33 | 5.27 ± 1.131 | 0.0001 | | BMI (kg/m2) | 28.5 ± 5.4 | 24.7 ± 4.1 | 0.0001 | | Fat mass (kg) | 20.4 ± 9.0 | 15.3 ± 8.2 | 0.001 | | Fat free mass (kg) | 55.5 ± 12.4 | 54.7 ± 9.6 | 0.707 | | Visceral fat mass (kg) | 8.5 ± 3.7 | 5.9 ± 4.2 | 0.001 | | Muscle mass (kg) | 53.6 ± 9.7 | 52.0 ± 9.2 | 0.341 | | PWv (m/s) | 7.37 ± 1.9 | 6.68 ± 2.16 | 0.033 | | PWv >7 m/s | 37 (63.8%) | 29 (23.8%) | 0.0001 | | LVMI (g/m2) | 151.9 ± 47.9 | 125.9 ± 45.05 | 0.001 | | LVMI >130 g/m2 | 37 (63.8%) | 29 (23.8%) | 0.001 | | ACEI | 7 (13.5%) | 21 (17.5%) | 0.339 | | AT II | 12 (23.1%) | 31 (25.8%) | 0.429 | | Statin | 12 (23.1%) | 26 (21.7%) | 0.492 | | Tacrolimus | 28 (54.9%) | 44 (41.9%) | 0.306 | | Cyclosporin-A | 13 (25.5%) | 33 (31.4%) | 0.149 | | Sirolimus | 10 (19.6%) | 28 (26.7%) | 0.306 | | CMV infection | 14 (24.5%) | 28 (26.7%) | 0.861 |
|
|
